117 related articles for article (PubMed ID: 24840518)
1. Management of advanced uterine leiomyosarcoma.
Hyman DM; Grisham RN; Hensley ML
Curr Opin Oncol; 2014 Jul; 26(4):422-7. PubMed ID: 24840518
[TBL] [Abstract][Full Text] [Related]
2. The biology and treatment of leiomyosarcomas.
Kerrison WGJ; Thway K; Jones RL; Huang PH
Crit Rev Oncol Hematol; 2023 Apr; 184():103955. PubMed ID: 36893945
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.
Turinetto M; Meeus P; Ray-Coquard I
Curr Opin Oncol; 2023 Jul; 35(4):288-291. PubMed ID: 37222199
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L
Curr Oncol; 2013 Oct; 20(5):e448-54. PubMed ID: 24155641
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy regimen for recurrent uterine leiomyosarcoma.
Hu F; Ye Y; Begum H
J Oncol Pharm Pract; 2024 Mar; 30(2):400-403. PubMed ID: 37787402
[TBL] [Abstract][Full Text] [Related]
6. Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine.
Arfan S; Thway K; Jones RL; Huang PH
Curr Treat Options Oncol; 2024 May; 25(5):644-658. PubMed ID: 38656686
[TBL] [Abstract][Full Text] [Related]
7. Treatment With Antitumor Agents Recommended by Cancer Genome Panel for Uterine Leiomyosarcoma.
Hayashi T; Kishimoto N; Abiko K; Konishi I
J Clin Med Res; 2023 Dec; 15(10-11):461-468. PubMed ID: 38189037
[TBL] [Abstract][Full Text] [Related]
8. The Future of Targeted Therapy for Leiomyosarcoma.
Denu RA; Dann AM; Keung EZ; Nakazawa MS; Nassif Haddad EF
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473300
[TBL] [Abstract][Full Text] [Related]
9. RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report.
Seryakov A; Magomedova Z; Suntsova M; Prokofieva A; Rabushko E; Glusker A; Makovskaia L; Zolotovskaia M; Buzdin A; Sorokin M
Front Oncol; 2021; 11():666001. PubMed ID: 34527573
[TBL] [Abstract][Full Text] [Related]
10. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).
Kasper B; Achee A; Schuster K; Wilson R; van Oortmerssen G; Gladdy RA; Hemming ML; Huang P; Ingham M; Jones RL; Pollack SM; Reinke D; Sanfilippo R; Schuetze SM; Somaiah N; Van Tine BA; Wilky B; Okuno S; Trent J
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672607
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment for uterine leiomyosarcomas.
Gadducci A; Guerrieri ME
Expert Opin Pharmacother; 2015 Feb; 16(3):335-46. PubMed ID: 25418060
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
[TBL] [Abstract][Full Text] [Related]
13. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Ricci S; Stone RL; Fader AN
Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
[TBL] [Abstract][Full Text] [Related]
14. The role of adjuvant therapy in uterine leiomyosarcoma.
Ducie JA; Leitao MM
Expert Rev Anticancer Ther; 2016; 16(1):45-55. PubMed ID: 26558647
[TBL] [Abstract][Full Text] [Related]
15. Soft Tissue and Uterine Leiomyosarcoma.
George S; Serrano C; Hensley ML; Ray-Coquard I
J Clin Oncol; 2018 Jan; 36(2):144-150. PubMed ID: 29220301
[TBL] [Abstract][Full Text] [Related]
16. Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin.
Amant F; Lorusso D; Mustea A; Duffaud F; Pautier P
Sarcoma; 2015; 2015():704124. PubMed ID: 26089739
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnosis and treatment of uterine sarcomas.
Dizon DS; Birrer MJ
Discov Med; 2014 Jun; 17(96):339-45. PubMed ID: 24979254
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.
Barlin JN; Zhou QC; Leitao MM; Bisogna M; Olvera N; Shih KK; Jacobsen A; Schultz N; Tap WD; Hensley ML; Schwartz GK; Boyd J; Qin LX; Levine DA
Neoplasia; 2015 Feb; 17(2):183-9. PubMed ID: 25748237
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
